Healthtech Solutions Inc. (HLTT) Enters Precision
Post# of 26
(Total Views: 179)
Posted On: 06/04/2021 4:41:25 PM
Healthtech Solutions Inc. (HLTT) Enters Precision Oncology Market with Acquisition of Varian Biopharmaceuticals
- Ability to tailor diagnostics, therapeutics to specific patients is key to precision medicine
- Global precision oncology market projected to grow at CAGR of 9.9% over the next eight years, will reach $99.7 billion by 2027
- Varian Bio making significant headway in development of two preclinical experimental cancer drugs
Healthtech Solutions (OTC: HLTT) is making a strong statement with its most recent acquisition. HLTT acquired Varian Biopharmaceuticals, a precision oncology company developing novel therapeutics for the treatment of cancer —and with the acquisition, the company is making its entry into the precision cancer care market (https://nnw.fm/gLdfb).
“Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare,” states a recent Research and Markets article (https://nnw.fm/4mr0Q). “The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of health care, and public investment led to the evolution of the personalization of disease-based therapies.
“This evolution within precision medicine will profoundly impact the biopharmaceutical industry,” continued the article. “Multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.”
A Precision Oncology Market analysis by Reports and Data noted that the global precision oncology market size totaled an estimated $49.9 billion in 2019; the report projects that the market will grow at a CAGR of 9.9% to reach $99.7 billion by 2027 (https://nnw.fm/7gLT9).
Led by its newest acquisition, Healthtech Solutions is positioning itself to be a leader in that burgeoning space. Varian Bio is developing a proprietary atypical protein kinase C iota (aPKCi) inhibitor for the treatment of various tumor types. Specifically, the company is making headway in the development of two preclinical experimental cancer drugs: VAR-101, a topical formulation for the treatment of basal cell carcinoma, the most common form of skin cancer (https://nnw.fm/XBZEG); and VAR-102, an oral formulation being evaluated for treatment of a variety of solid tumors, including pancreatic, colorectal and non-small cell lung cancer (“NSCLC”).
“Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
Varian Bio’s drug candidates — VAR-101 and VAR-102 — leverage the company’s expertise. In addition to the strides the company is making in precision oncology, HealthTech is also developing technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology, being developed by subsidiary Medi-Scan Inc., has multiple applications in lung, cardiac and musculoskeletal imaging and related uses.
For more information, visit the company’s website at www.HealthTechSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Ability to tailor diagnostics, therapeutics to specific patients is key to precision medicine
- Global precision oncology market projected to grow at CAGR of 9.9% over the next eight years, will reach $99.7 billion by 2027
- Varian Bio making significant headway in development of two preclinical experimental cancer drugs
Healthtech Solutions (OTC: HLTT) is making a strong statement with its most recent acquisition. HLTT acquired Varian Biopharmaceuticals, a precision oncology company developing novel therapeutics for the treatment of cancer —and with the acquisition, the company is making its entry into the precision cancer care market (https://nnw.fm/gLdfb).
“Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare,” states a recent Research and Markets article (https://nnw.fm/4mr0Q). “The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of health care, and public investment led to the evolution of the personalization of disease-based therapies.
“This evolution within precision medicine will profoundly impact the biopharmaceutical industry,” continued the article. “Multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.”
A Precision Oncology Market analysis by Reports and Data noted that the global precision oncology market size totaled an estimated $49.9 billion in 2019; the report projects that the market will grow at a CAGR of 9.9% to reach $99.7 billion by 2027 (https://nnw.fm/7gLT9).
Led by its newest acquisition, Healthtech Solutions is positioning itself to be a leader in that burgeoning space. Varian Bio is developing a proprietary atypical protein kinase C iota (aPKCi) inhibitor for the treatment of various tumor types. Specifically, the company is making headway in the development of two preclinical experimental cancer drugs: VAR-101, a topical formulation for the treatment of basal cell carcinoma, the most common form of skin cancer (https://nnw.fm/XBZEG); and VAR-102, an oral formulation being evaluated for treatment of a variety of solid tumors, including pancreatic, colorectal and non-small cell lung cancer (“NSCLC”).
“Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
Varian Bio’s drug candidates — VAR-101 and VAR-102 — leverage the company’s expertise. In addition to the strides the company is making in precision oncology, HealthTech is also developing technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology, being developed by subsidiary Medi-Scan Inc., has multiple applications in lung, cardiac and musculoskeletal imaging and related uses.
For more information, visit the company’s website at www.HealthTechSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Healthtech Solutions Inc. (HLTT) Stock Research Links
Scroll down for more posts ▼